BioStem Technologies (OTCMKTS:BSEM – Get Free Report) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.50) per share and revenue of $6.3520 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.
BioStem Technologies (OTCMKTS:BSEM – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The firm had revenue of $6.14 million during the quarter, compared to analysts’ expectations of $5.70 million. On average, analysts expect BioStem Technologies to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
BioStem Technologies Stock Performance
BSEM opened at $3.26 on Wednesday. BioStem Technologies has a 12-month low of $3.01 and a 12-month high of $11.54. The company has a market cap of $58.09 million, a price-to-earnings ratio of -2.92 and a beta of 0.11. The stock has a fifty day simple moving average of $3.69 and a two-hundred day simple moving average of $4.65.
Analysts Set New Price Targets
Get Our Latest Research Report on BioStem Technologies
BioStem Technologies Company Profile
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.
Featured Articles
- Five stocks we like better than BioStem Technologies
- CoreWeave Powers Up: The Asia Infrastructure Grab
- Boot Barn Stock Still Has Room to Run, But It Must Earn Its Premium
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
Receive News & Ratings for BioStem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioStem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
